Even though the log-rank p-values were significant for TP53 and GATA3 mutations in both groups, survival analyses including tumors harboring alterations only in each of the most frequently mutated genes, but not in the others, revealed that in ER+/PR− breast cancers only TP53 mutations are related to a different prognosis (Figure 3). The gene discussed is ESR1; the disease is breast carcinoma.